Reports Q4 revenue $65.65B, consensus $63.18B. “While higher medical costs in our stop loss product impacted fourth quarter earnings, we are taking corrective actions to address these near-term pressures and we are simultaneously taking steps to further advance our long-term growth strategy,” said David Cordani, chairman and CEO of The Cigna (CI) Group. “Through a dynamic environment, we are continuing to focus on building a sustainable model for healthcare by addressing the areas that matter most to our patients and clients, including greater transparency, support, and value.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Notable companies reporting before tomorrow’s open
- Medicare, Medicaid not impacted by Trump funding freeze, Politico reports
- Medicaid insurers slip as Trump administration pauses assistance program payouts
- Is CI a Buy, Before Earnings?
- FTC Slams UnitedHealth (NYSE:UNH), CVS and Cigna PBMs for Inflating Prices by $7.3B